Experts highlighted how Diamond-Blackfan anemia illustrates the scientific, financial, and manufacturing challenges that can prevent promising gene therapies for ultra-rare diseases from reaching patients.
|Articles|April 1, 2004
- Volume 0 0
TampAlerT
Advertisement
TampAlerT, manufactured by Medi- Dose/EPS, Inc (Ivyland, Pa), is a unique system that allows practitioners to package liquids, solids, or powders in unit doses with tamper-evident seals. TampAlerT is perfect for legend drugs and controlled substances, inpatient, or afterhours dispensing. It is available in vial sizes from 15 mL to 120 mL in natural or white ultraviolet-inhibitant polyethylene with regular or child-resistant caps. For more information: 888-TAMPALERT or 800-523-8966 www.medi-dose.com
Articles in this issue
over 22 years ago
RxPRODUCT NEWS PROFILE: Caduetover 22 years ago
COMPOUNDING HOTLINEover 22 years ago
Case Studiesover 22 years ago
Buddies Are Good for the Heartover 22 years ago
Low-Fat Diet Shows Promise for Prostate Cancerover 22 years ago
Rage Is Connected to Stroke Riskover 22 years ago
InnoLetover 22 years ago
Colace/Peri-Colaceover 22 years ago
Low Testosterone Is Linked with Alzheimer's Diseaseover 22 years ago
Wound Care in an Aging Population: Special ConsiderationsAdvertisement
Related to this article
Experts highlighted recent gene therapy approvals for inherited immune disorders while addressing ongoing challenges in manufacturing, long-term safety, and patient access.
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
At the 2026 ASTCT Gene Therapy Summit, experts highlighted how chronic pain, psychological challenges, and neurologic complications may persist despite successful treatment.
RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.
ADA guidance ties monitoring choices to therapy, risk, and preference. Brooke Hudspeth, PharmD, explains how pharmacists help individualize the plan.
Twice-daily metronidazole dosing had outcomes comparable with those of thrice-daily dosing for confirmed anaerobic infections, minimizing drug exposure and cost while maintaining clinical efficacy.
Pharmacists navigate BCMA therapy sequencing in relapsed/refractory multiple myeloma, weighing linvoseltamab logistics, community readiness, safety monitoring, and smoother care transitions.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CVS Health to Split Into 2 Public Companies, Separating Retail and Specialty Pharmacy
2
Two Gene Therapy Approvals Expand Options for Rare Immune Disorders as Access Challenges Persist
3
Is Less More? Comparing Metronidazole Dosing in Confirmed Anaerobic Infections
4
RSV Hospitalization Linked to Higher Short-Term Risk of Invasive Pneumococcal Disease
5